Practical guidance on the use of faecal calprotectin

被引：32

作者：

Brookes, Matthew J. ^{[1
]}

Whitehead, Simon ^{[2
]}

Gaya, Daniel R. ^{[3
]}

Hawthorne, Antony Barney ^{[4
]}

机构：

[1] Royal Wolverhampton NHS Trust, Gastroenterol Dept, Wednesfield Rd, Wolverhampton WV10OQP, W Midlands, England

[2] Royal Wolverhampton Hosp NHS Trust, Dept Clin Chem, Wolverhampton, W Midlands, England

[3] Glasgow Royal Infirm, Dept Gastroenterol, Glasgow, Lanark, Scotland

[4] Univ Hosp Wales, Dept Med, Cardiff, S Glam, Wales

来源：

FRONTLINE GASTROENTEROLOGY | 2018年 / 9卷 / 02期

关键词：

D O I：

10.1136/flgastro-2016-100762

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Differentiation between inflammatory bowel disease (IBD) and functional gut disorders, and the determination of mucosal disease activity in established cases of IBD remain the cornerstones of disease diagnosis and management. Non-invasive, accurate biomarkers of gut inflammation are needed due to the variability of symptoms, the inaccuracies of currently available blood markers and the cost and invasive nature of endoscopy. Numerous biomarkers have been used and/or considered with some in current use. This article reviews the current evidence base around the indications for using biomarkers and their limitations, with a particular focus on faecal calprotectin.

引用

页码：87 / 91

页数：5

共 56 条

[1] Fecal MMP-9: A New Noninvasive Differential Diagnostic and Activity Marker in Ulcerative Colitis [J].

Annahazi, Anita ;

Molnar, Tamas ;

Farkas, Klaudia ;

Rosztoczy, Andras ;

Izbeki, Ferenc ;

Gecse, Krisztina ;

Inczefi, Orsolya ;

Nagy, Ferenc ;

Foeldesi, Imre ;

Szucs, Monika ;

Dabek, Marta ;

Ferrier, Laurent ;

Theodorou, Vassilia ;

Bueno, Lionel ;

Wittmann, Tibor ;

Roka, Richard .

INFLAMMATORY BOWEL DISEASES, 2013, 19 (02) :316-320

[2]

[Anonymous], 2013, FAEC CALPR DIAGN TES

[3] Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity [J].

Berrill, J. W. ;

Green, J. T. ;

Hood, K. ;

Campbell, A. K. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (01) :44-51

[4] Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease [J].

D'Haens, Geert ;

Ferrante, Marc ;

Vermeire, Severine ;

Baert, Filip ;

Noman, Maja ;

Moortgat, Liesbeth ;

Geens, Patricia ;

Iwens, Doreen ;

Aerden, Isolde ;

Van Assche, Gert ;

Van Olmen, Gust ;

Rutgeerts, Paul .

INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) :2218-2224

[5] Crohn's disease management after intestinal resection: a randomised trial [J].

De Cruz, Peter ;

Kamm, Michael A. ;

Hamilton, Amy L. ;

Ritchie, Kathryn J. ;

Krejany, Efrosinia O. ;

Gorelik, Alexandra ;

Liew, Danny ;

Prideaux, Lani ;

Lawrance, Ian C. ;

Andrews, Jane M. ;

Bampton, Peter A. ;

Gibson, Peter R. ;

Sparrow, Miles ;

Leong, Rupert W. ;

Florin, Timothy H. ;

Gearry, Richard B. ;

Radford-Smith, Graham ;

Macrae, Finlay A. ;

Debinski, Henry ;

Selby, Warwick ;

Kronborg, Ian ;

Johnston, Michael J. ;

Woods, Rodney ;

Elliott, P. Ross ;

Bell, Sally J. ;

Brown, Steven J. ;

Connell, William R. ;

Desmond, Paul V. .

LANCET, 2015, 385 (9976) :1406-1417

[6] Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis [J].

De Vos, M. ;

Dewit, O. ;

D'Haens, G. ;

Baert, F. ;

Fontaine, F. ;

Vermeire, S. ;

Franchimont, D. ;

Moreels, T. ;

Staessen, D. ;

Terriere, L. ;

Vander Cruyssen, B. ;

Louis, E. .

JOURNAL OF CROHNS & COLITIS, 2012, 6 (05) :557-562

[7] Faecal Calprotectin in Suspected Paediatric Inflammatory Bowel Disease [J].

Degraeuwe, Pieter L. J. ;

Beld, Monique P. A. ;

Ashorn, Merja ;

Canani, Roberto Berni ;

Day, Andrew S. ;

Diamanti, Antonella ;

Fagerberg, Ulrika L. ;

Henderson, Paul ;

Kolho, Kaija-Leena ;

Van de Vijver, Els ;

van Rheenen, Patrick F. ;

Wilson, David C. ;

Kessels, Alfons G. H. .

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2015, 60 (03) :339-346

[8] Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? [J].

Dhaliwal, A. ;

Zeino, Z. ;

Tomkins, C. ;

Cheung, M. ;

Nwokolo, C. ;

Smith, S. ;

Harmston, C. ;

Arasaradnam, R. P. .

FRONTLINE GASTROENTEROLOGY, 2015, 6 (01) :14-19

[9] Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology [J].

Dolwani, S ;

Metzner, M ;

Wassell, JJ ;

Yong, A ;

Hawthorne, AB .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (06) :615-621

[10]

Ertekin V, 2010, J CLIN GASTROENTEROL, V44, P544, DOI [10.1097/MCG.0b013e3181cadbco, 10.1097/MCG.0b013e3181cadbc0]

← 1 2 3 4 5 6 →